Small but Important Differences Seen Between Rosuvastatin, Atorvastatin
Rosuvastatin tied to cardiovascular and mortality benefits but also higher risk for type 2 diabetes
ASN: Atrasentan Significantly and Clinically Meaningfully Cuts Proteinuria
Findings seen in patients with IgA nephropathy, compared with placebo
ASN: Hypertension Most Common Cardiovascular Comorbidity Seen With Dialysis
The next most common conditions included atherosclerotic heart disease and congestive heart failure
Many Seniors at Risk for Financial Precarity From Cost of Hospital Stay
Financial precarity more prevalent among Black and Hispanic versus White, those with less versus more than high school education
ASN: Recurrent UTIs Impact eGFR in Children With Vesicoureteral Reflux
Recurrent urinary tract infections linked to decrease of up to 27 mL/min/1.73 m² in estimated glomerular filtration rate
ASN: Empagliflozin Offers Lasting Cardiorenal Benefit in CKD Patients
Empagliflozin offers cardiorenal benefits for up to 12 months after discontinuation among CKD patients at risk for progression
Artificial Intelligence Model Predicts Kidney Graft Survival
UK-DTOP model shows marked improvement compared with traditional Kidney Donor Risk Index
FDA Appoints New Head of Medical Devices
Novel Imaging Technique Accurate for Detecting Clear-Cell Renal Cell Cancer
In a recent study, mean sensitivity was 85.5 percent and specificity 87 percent for detection of clear-cell renal cell carcinoma
Varying Dialysate Calcium Dosage Not Tied to Differences in All-Cause, Cardiovascular Mortality
Findings seen for 1.50 versus 1.25 mmol/L in patients undergoing hemodialysis
